Current therapy of retrolental fibroplasia. Retinopathy of prematurity.
Retrolental fibroplasia, frequently referred to now as the "retinopathy of prematurity," has shown an increased incidence in recent years. This is apparently due to advances in neonatal care, which have resulted in a four- to five-fold improvement in the survival of the extremely low birthweight infants and it is these infants who are at the highest risk of developing retrolental fibroplasia. The use of large supplements of vitamin E, a known antioxidant, is discussed along with other forms of therapy.
D002648:Child; D002986:Clinical Trials as Topic; D003452:Cryosurgery; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007273:Injections, Intramuscular; D008028:Light Coagulation; D012178:Retinopathy of Prematurity / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D014810:Vitamin E / Q000627:therapeutic use*
D014810:Vitamin E